HomeAI · summaries
Storia in 10 fonti
One dose of gene-editing drug cut bad cholesterol 62% for months in small trial
The interim Phase I trial data was only from 35 people, but results look good so far.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Early data for heart drug affirm Lilly’s billion-dollar bet on Verve
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
- ·
benzinga.com
Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Eli L
Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.
